Disposable Solutions for Bio Manufacturing
2020-02-18 - 2020-02-20 | Leonardo Royal Hotel Berlin Alexanderplatz, Berlin, Germany, Germany
Now in it’s 12th year, the 2020 Disposable Solutions for Biomanufacturing Forum is the only global forum that focuses on the use of disposable products and single use systems in biomanufacturing. Our attendees will be guided through their journey and understand how they can run 100% disposable sites and scale their manufacturing capabilities with our newly designed program focused on implementation, systems management and future technology.

The three packed days will consist of case studies and interactive sessions to identify new technologies, determine how to approach automated systems, transition to continuous processes and learn how to implement best practice in system testing & life cycle management!
To learn more about Disposable Solutions for Bio Manufacturing and to register online, visit http://bit.ly/2Mp6lEs

RNA Therapeutics
2020-02-19 - 2020-02-20 | London, UK, United Kingdom
SMi Group are pleased to present the 11th Annual RNA Therapeutics Conference and Focus Day in London on February 18th – 20th 2020.
The field of RNA therapeutics is rapidly expanding, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

The event will focus on the latest research and developments on delivery system technologies that aim to tackle more difficult targets within the human body. This overarching topic warrants high focus and therefore, for the first time in the series, introduce a focus day on Oligonucletide Delivery Systems. The main conference will focus on current developments in the area of mRNA therapeutics in immunotherapy and vaccination.
NEW FOR 2020: RNA Therapeutics Focus Day – Oligonucleotide Delivery Systems
Introducing the only RNA therapeutics conference to hold a full day exploring alternatives to oligonucleotide delivery systems. The global antisense and RNA therapeutics market is expected to expand at a compound annual growth rate (CAGR) of 8.6% between 2019 and 2025, projected to reach $1.81 billion, this focus day will assess the growing need for research and development of novel delivery approaches to expand the current delivery methods in today’s market.
How will you benefit?

Discuss the innovations in oligonucleotide delivery systems
Explore the latest developments in RNA delivery agents and RNA-based therapeutics
Learn from case studies on clinical developments with leading RNA therapeutics companies and regulatory bodies
Revisit the challenges for clinical translation of RNA-based therapeutics
Evaluate the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing
Gain an expert view on new and upcoming regulatory updates and industry implications

Network and learn from leading professionals such as:
CHAIR FOR 2020
Heinrich Haas, VP RNA Formulation and Drug Delivery, BioNTech
FEATURED SPEAKERS INCLUDE:

Shalini Andersson, Chief Scientist New Therapeutic Modalities, AstraZeneca
Christian Plank, CTO, Ethris
Steve Pascolo, Founder and CEO, Miescher Pharma
Kirsty Wydenbach, Deputy Unit Manager, Clinical Trials Unit, MhRA
Steven Powell, CEO, eTheRNA
Simon Newman, CSO, Nanogenics
Christiane Niederlaender, Director, AMBR Consulting and Formerly,
Quality Assessor, Biologicals, MhRA
Klaus Giese, CEO, Pantherna Therapeutics
David Blakey, CSO, MiNA Therapeutics
Jeffrey Ulmer, Head Preclinical R&D, GSK

For more information and to register, visit: www.therapeutics-rna.com/pjwb
Early-Bird Rates
REGISTER BY 31ST OCTOBER TO SAVE £400
REGISTER BY 29Th NOVEMBER TO SAVE £200
REGISTER BY 13Th DECEMBER TO SAVE £100
Social Media Handles
Follow us on LinkedIn ‘SMi Pharma’, Twitter @SMiPharm and use #SMiRNA

SMi’s 4th Annual 3D Cell Culture
2020-02-19 - 2020-02-20 | Copthorne Tara Hotel, London, UK, United Kingdom
CHAIRED BY:
Philip Hewitt, UK and Eurotox Registered Toxicologist, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA
Stefan Przyborski, Professor of Cell Technology, Durham university
Development and application of human organs and tissues in vitro
Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.

SMi’s 3D Cell Culture Conference will explore advances of organ and lab-on-a-chip, microphysiological systems, applications of technology and case studies, imaging, high throughput screening and advances in 3D cell culture models which make up core components within the 3D Cell Culture field.
Bioprinting has become increasingly efficient and accurate in building in vitro tissue models with the potential to provide pathologically relevant responses and model human disease mechanisms. Bio-printed structures yield phenotypic endpoints that are comparable with clinical studies and can provide a realistic prediction of clinical efficacy. The use of bioprinting is growing in big pharma companies as an alternative to organ-on-a-chip systems.
For the first time ever the NEW 3D Bioprinting Focus Day on 18 February 2020 will explore case studies from big pharma, biotech’s and academia exploring how bioprinting is being used in industry highlighting projects looking at stem cell therapy, drug screening and extracellular matrix scaffolds.
Event Hashtag: #SMi3DCellCulture
FEATURED SPEAKERS INCLUDE:

Leonard Both, Senior Quality Assessor, Biologicals/Biotechnology Unit, MHRA
Veronique Barban, Expert Virology, Research and Nonclinical Safety Department, Sanofi Pasteur
Simone Stahl, Associate Principal Scientist, ADME Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca
Wendy Rowan, Scientific Director, Novel Human Genetics Research Unit, GSK
Jason Ekert, Head of Complex In Vitro Models, GSK
Samuel Jackson, Programme Manager, Disease Models Efficacy and Safety Pharmacology, NC3RS

KEY TOPICS FOR 2019 INCLUDE:

Learn from leading pharma companies to benchmark against their applications of 3D technology
Explore case studies of 3D cell culture, high throughput screening, imaging and microphysiological systems in industry
Hear about the latest technology advances allowing 3D bioprinting to revolutionise in vitro models
Discuss organ-on-chip technologies and their applications to replace the use of animals in pharmaceutical research
Participate in a panel discussion on adopting new technologies for 3D models

View the full agenda: http://www.3d-cellculture.com/PJWL
WHO SHOULD ATTEND?
Biotech / Pharma Companies – Team Leader, Junior Principle investigator, Cell and Molecular Scientist, Chief Scientific Officer, Deputy Director, Manager, Founder, CEO, Head, Director, Programme Manager, Lab Head, Toxicologist
Academia Professor – Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering
Solution Providers – Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director, Vice President, COO
Organisations / Regulatory – Director, Senior Science Advisor, Scientific Officer
EARLY BIRD-RATES

REGISTER BY 31ST OCTOBER AND SAVE £400
REGISTER BY 29TH NOVEMBER AND SAVE £200
REGISTER BY 13TH DECEMBER AND SAVE £100

CAR-TCR Europe Summit
2020-02-24 - 2020-02-27 | Novotel London West, Hammersmith, London, W6 8DR
With CAR-T therapies on the cusp of achieving global approval, there are still many bottlenecks that are preventing this from becoming the ‘sell-out’ therapy that the field had hoped for. The CAR-TCR Europe Summit will unravel the technical challenges across translation, scale and delivery to provide your team with the platform to learn, collaborate and gain actionable insights to advance your therapy for clinical and commercial success.
This focused agenda will delve into the technical bottlenecks encountered in every stage of the CAR-TCR drug development cycle, providing a comprehensive analysis across 3 tracks including: Translational, Manufacturing & Clinical
To learn more about CAR-TCR Europe Summit and to register online, visit https://ter.li/9iuqer

3rd Antigen Specific Immune Tolerance Summit
2020-02-25 - 2020-02-27 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116
Translating Emerging Antigen Specific Immune Tolerance Approaches for Therapeutic Applications
Accelerate the progression of ethical and effective antigen specific immunotherapies through the clinic, optimize the discovery of novel targets and explore novel therapeutic approaches harnessing combination therapies.

Building on the success of the 2019 meeting, the 3rd Antigen Specific Immune Tolerance Summit (ASIT) returns to Boston on February 25-27, 2020. The meeting will bring together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies, ASIT 2020 is the only antigen specific summit offering thought leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development.

Hear from and engage with a world-class speaking faculty made up of 26 industry representatives including Novo Nordisk, Pfizer, Merck, Eli Lilly, ITN & FDA
Explore cross learning opportunities from parallel fields tackling immune tolerance and better understand the fundamental mechanisms that lie behind tolerance induction
Engage with and immerse yourself within a learning journey across three conference days, tackling all elements of drug development from discovery to clinical development
Gain practical insight from those describing recent clinical trials and determine what mechanisms lie behind successful and unsuccessful clinical trials
Employ novel therapeutics in combination with antigen specific immunotherapies and drive the progression of drug development towards the clinic
Take advantage of intimate networking opportunities with key opinion leaders from large pharma, biotech and academia through discursive and engaging platforms that spark conversation and debate

To learn more about 3rd Antigen Specific Immune Tolerance Summit and to register online, visit https://ter.li/rp07a3

RAS- Targeted Drug Discovery Summit Europe
2020-02-25 - 2020-02-27 | Hilton Vienna Plaza, Schottenring 11, Vienna, A - 1010, Austria
After three decades of trial and error to target the driver of 30% of all diagnosed cancers, scientists are finally making meaningful clinical progression to target the cancer master switch, the RAS family of proteins.

The RAS- Targeted Drug Discovery Summit Europe is the only industry-led and translational focused platform dedicated to bringing you innovative anti-RAS drug discovery science, capturing the most pioneering data, thought-provoking insights and practical lessons learned, enabling you to maximise the clinical therapeutic window of your anti-RAS candidate. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic. Hear from the likes of Boehringer Ingelheim, Sanofi, Bayer, Francis Crick Institute, PhoreMost, Allinky Biopharma, Elicio Therapeutics, Oblique Therapeutics, Onconova Therapeutics and Revolution Medicines. Visit the website to see the full speaker line-up, what will be discussed, pricing and ticket options: https://ter.li/8qb2rr.

8th Neurodegenerative Drug Development Summit
2020-02-25 - 2020-02-27 | Hyatt Regency Boston, 1 Avenue de Lafayette, Boston, MA, 02111, United States
Returning to Boston in February 2020 is the 8th Neurodegenerative Drug Development Summit, previously World CNS.
Despite the lack of clinical trial success, new investments are being made in forward-thinking biotechs, digital and blood-based biomarker technologies are advancing, new targets are emerging, and gene therapy is taking the limelight.
The Neurodegenerative Drug Development Summit will unite industry stakeholders to learn how to overcome their translational challenges, share their progress and network for future collaborations to accelerate the development of successful neurodegenerative therapeutics.
Don’t miss your opportunity to join over 150 fellow CNS experts from Biogen, AbbVie, Sanofi and more, and immerse yourself in the neurodegenerative community to help refresh the neurodegenerative approach and challenge traditional thinking to advance clinical progress.

21st Pharmacovigilance 2020
2020-02-26 - 2020-02-27 | Pestana Chelsea Bridge Hotel, London, United Kingdom
“Latest developments in pharmacovigilance, drug safety and RMP”
21st Pharmacovigilance 2020 event keeps an immersed eye on discussion of critical topics in PV domain, which capture influence of emerging technologies like AI, IoT, Big Data. Not merely that, we have exciting surprise activities which will help you to interact more with your peers. This will be surely an exciting event wherein you could get chance to meet big industry gems. Let’s gather to shape the industry with your magnificent ideas.

SPONSORS:

Covance
Brookwood Global

We also have more sponsorship opportunities available for the event, which gives you an opportunity to sponsor/speak/exhibit/Booth/Stall and create brand awareness. In addition, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts.
DELEGATE REGISTRATION:
In order to register please contact us on Email: kavitha@virtueinsight.co.in
1 Delegate @ £1299 + VAT
3 Delegates @ £2598 + VAT
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

Animal Microbiome & Nutritional Health Congress
2020-03-03 - 2020-03-04 | Warwick Allerton – Chicago, 701 N Michigan Avenue, Chicago, IL, 60611, United States
Building on the huge success of our European Animal Microbiome Congress in London this past July, we are incredibly excited to return to the USA in March 2020, this time in Chicago, Illinois.

Interest in animal microbiomes as therapeutics is rapidly expanding, as techniques to study the microbial world decrease in cost and increase in accessibility, and case studies from human medicine receive widespread attention. The current state of techniques and strategies to modify the microbiome to improve animal health, focusing on applications in domestic pets and farm animals, will be the main focus of this event.
We will be untangling the basic biology of microbiome-directed therapies in animals and the examples to date of application of probiotics, prebiotics, and other microbiome-directed therapies and feed additives being used to benefit animal health. We will also be looking heavily at the impact of different feed and nutrition profiles on animal microbiomes, and the power of nutrition in affecting animal health in a beneficial way.
Finally, the event will host the Animal Microbiome & Nutritional Health Innovation Showcase, where 8 emerging companies in the field of animal nutrition will present the microbiome and nutritional solutions they can bring to market.
To learn more about this event and to register online, visit https://animalmicrobiomecongressusa.com/

Gene Therapy for Blood Disorders
2020-03-03 - 2020-03-05 | Courtyard Boston Downtown, 275 Tremont Street, Boston, MA, 02116, United States
Discover the Clinical & Commercial Potential of Gene Therapy & Editing Approaches Revolutionizing Hemophilia, Sickle Cell Disease & β-Thalassemia Treatment
Revolutionary gene therapies are redefining the treatment of blood diseases.

With an approved gene therapy treatment for β-thalassemia in the EU, and hemophilia candidates seeking 2020 approval in the USA and beyond, pioneers in the space must overcome hurdles they have never previously encountered to transform their clinical candidates into a commercial reality. Gene Therapy for Blood Disorders will unite industry leaders across the blood disease space to delve into the specific clinical and commercial challenges faced by companies developing gene therapies for hemophilia, sickle cell disease and
β-thalassemia.
Evaluate the best strategies for a commercial launch in blood disease, optimize your trial design, gain insights on revolutionary novel technologies, and ultimately enhance your current hematology gene therapy program to bring transformative treatments to patients more quickly and efficiently.
Download the full event guide to learn more from companies including bluebird bio, Spark Therapeutics and Editas Medicine

8th Annual Pharma AntiCounterfeiting & Serialisation 2020
2020-03-04 - 2020-03-05 | Pestana Chelsea Bridge Hotel, London, United Kingdom
8th Annual Pharma AntiCounterfeiting & Serialisation 2020 will provide you insight into the current state of play in the EU & US on the vital role of technology impact in the sustainability of pharma and healthcare systems. Our speakers will outline the key recent developments in technology impact in pharma and healthcare in the EU and other international jurisdictions. The event will also address some of the most achievable possibilities of integrating AI, IoT and blockchain within pharma and healthcare through a mixture of practical, lectures and roundtable discussions specifically designed.
CONFERENCE SPONSORS:

IO AG

We have sponsorship opportunities available for the event, which gives you an opportunity to sponsor/speak/exhibit/stall/booth and create brand awareness. In addition, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. For further details please contact Kavitha at Email: kavitha@virtueinsight.co.in
CONFERENCE DELEGATE PRICING:
In order to Register as delegate for the conference please contact Kavitha at kavitha@virtueinsight.co.in
Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event.

Early Bird Discount Price:
1 Delegate @ £899 + VAT (Valid Till 24th Jan 2020)
3 Delegates @ £1798 + VAT (Valid Till 25th Jan 2020)
Standard Price:
1 Delegate @ £1299 + VAT (Valid from 25th Jan 2020)
3 Delegates @ £2598 + VAT (Valid from 25th Jan 2020)
KEY SPEAKERS:

NICHOLAS CALL, Special Agent, FDA
GALIT MEYRAN, Serialization Global Program Manager, Teva
MARCEL DE GRUTTER , Project Manager Serialization – Regulatory & Government Affairs Liaison, Abbott
PATRIK MERCKELL, External Business Process Analyst and Project Manager, Roche
EIKE HILLBRICHT , Corporate Security Manager, Boehringer Ingelheim
JACK JING , Global Business Development Director / Head of EU Commercial Operations, Seacross Pharmaceuticals
LEYLA HANNBECK , CEO, Association of Independent Multiple Pharmacies
SULTAN DAJANI , Pharmacist Superintendent, Wainwrights Chemists
TRACQ ANTOINE, Head of Commercial Logistics & Serialization, Galderma
ADRIAN VAN DEN HOVEN, Director General of Medicines for Europe, European Medicines Verification Organisation (EMVO)
MIKE ISLES, Executive Director, European Alliance for Access to Safe Medicines
MONIKA DERECQUE POIS, Director General, GIRP—European Healthcare Distribution Association
BILL ARONSON , COO, Artificial Intelligence Research Group
MARIE MANLEY , Partner, Head of the UK Life Sciences Practice, Sidley Austin
SANDY EISEN, Chief Medical Officer, Fromtline Pharma

Plus many more
KEY THEMES:
Anti-counterfeiting, Serialisation, T&T

Shaping the future for Healthcare
Effect of Post (FMD) Deadline
Serialisation strategies- Choosing a Serialisation solution
AI algorithms to crack down on fake products
Fight the FAKE – Protect the public
Technology Impact – Current digital world
Serialisation and Compliance
Penetrating the legitimate supply chain
Packaging Techniques – Protecting your products

Brexit

Impact on EU, US and Row market

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading companies showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

3rd Annual Phrama AI, IoT & Blockchain 2020
2020-03-04 - 2020-03-05 | Pestana Chelsea Bridge Hotel, London, United Kingdom
“Competences to Combat Counterfeits & Impact of AI, IoT, Blockchain & Big Data in Pharma”
Our 3rd Annual Pharma AI, IoT & Blockchain 2020 will provide you insight into the current state of play in the EU & US on the vital role of technology impact in the sustainability of pharma and healthcare systems. Our speakers will outline the key recent developments in technology impact in pharma and healthcare in the EU and other international jurisdictions. The event will also address some of the most achievable possibilities of integrating AI, IoT and blockchain within pharma and healthcare through a mixture of practical, lectures and roundtable discussions specifically designed.
SPONSORS:

io AG
Advanco

We have more sponsorship opportunities available for the event, which gives you an opportunity to sponsor/speak/exhibit/stall/booth and create brand awareness. In addition, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. For further details please contact Kavitha at Email: kavitha@virtueinsight.co.in

CONFERENCE DELEGATE PRICING:
Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event.
In order to Register as delegate for the conference please contact Kavitha at kavitha@virtueinsight.co.in
1 Delegate @ £1299 + VAT
3 Delegates @ £2598 + VAT
KEY SPEAKERS:

STEVEN ABRAHAMSON, Senior Director, Product Cyber Security, GE Healthcare
PATRIC JARCHOW , Head of Global Multi-Channel Strategy, Merck KGaA
NICLAS NILSSON , Head of Open Innovation in Research, LEO Pharma
STEVEN WILLIAMSON, Audit Account Director, Information Security, GSK
EDDIE GUZDAR , Medical Head UK & Ireland | Physician | Venture Capital & Board Advisor – Digital Technology, Sanofi Genzyme
NATALIA M.MONTEIRO, Clinical Trial Budget & Metrics Management, Takeda Pharmaceuticals
PINGPING NI, Director, Biometrics Team Lead, AstraZeneca
ALAN HOW, Strategy & Operations – Global Commercial, Merck
HUSSAIN AL MUSCATI , Customer Engineering Lead, Life Sciences, Google
MARCO GUIDOBALDI , Sales Engineer – Healthcare & Life Sciences, Google
EBERHARD SCHEUER , Chairman, HIT Foundation
GABOR PURMAN , Senior Account Director, Patient Services and Medical Education, NexGen Healthcare Communications
ROMIKA BHOWMICK, Senior Manager – Digital Commercial (Europe & International Markets), Teva
BRAM VAN LEEUWEN , Lead (digital) Innovation BeNeLux, Sanofi
EVI MATHIOU, Legal, Compliance & Quality Manager BA Europe East & South, Novo Nordisk
MYLES FURNACE, Digital Health and Data Lead, UK & Ireland Speciality Care, IPSEN
RAMESH KRISHNAMURTHY , Strengthen international institutions, WHO (World Health Organization)
SIDDHI TRIVEDI , Healthcare Innovator, Co-founder, Beyond Identity
ALF GOEBEL, CEO, Advanco
IGNACIO H. MEDRANO, Founder & Chief Medical Officer, SAVANA
EDITH LECOMTE NORRANT , CEO & CSO, IPSOMEDIC
ROBIN SMITH, Security and Information Assurance Lead, Independent Office for Police Conduct (IOPC)

Plus many more
KEY THEMES:
AI and IoT

Applications in Pharma and Healthcare
Challenges and opportunities
Use of AI in drug discovery
Role of Cyber Security in age of IoT and Healthcare Hacks
IP – Cybercrime in the pharmaceutical industry: a booming business
Transforming the healthcare and pharmaceutical industry

Blockchain

How it transforms pharma and healthcare
Blockchain in Logistics and Supply Chain
A must learn technology
Blockchain technology and start-ups – where do you get started?
Application areas for blockchain within healthcare?

Big Data

Potential future in synchronicity of data
Big data =Big impact
A Revolution in Drug Discovery and Pharma R&D
How to involve patients better to develop drugs

Brexit

Impact on EU, US and Row market

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading companies showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

Inborn Errors of Metabolism Drug Development
2020-03-10 - 2020-03-12 | Courtyard Boston Downtown/North Station, 107 Beverly Street, Boston, MA, 02114, United States
Join over 80 inherited metabolic disease drug developers and KOLs to explore how the key challenges prohibiting accelerated drug development are being addressed. The inaugural Inborn Errors of Metabolism Drug Development Summit will provide a discursive platform to examine where pioneering gene therapy modalities intersect with current therapeutic options and explore how diseases can be better targeted in order to address the huge unmet medical need for rare metabolic diseases.
With scarce treatment options leaving inborn errors of metabolism a devastating, unfilled and unmet medical need, the opportunity for biopharma to do better and aggressively tap into a lucrative and life changing market of gene modalities is growing. For the first time, the Inborn Errors of Metabolism Drug Development summit will look to examine how the experience within existing pharmacology for rare metabolic diseases can be leveraged with the drug development strategies of those pioneering gene modalities to improve efficacy, safety and commercial viability.
Incorporating insights from industry-leading speakers, this conference will delve into the key patient access, regulatory, clinical and commercial hurdles that need to be overcome in order to address the unmet medical need of rare metabolic diseases and fulfil their full commercial potential.
This is your comprehensive guide to define your drug development path for 2020. Don’t miss out on your chance to network with industry leaders and be a part of the only enriched industry forum focused on accelerating the development of better effective treatments for inborn errors of metabolism.
To know more about Inborn Errors of Metabolism Drug Development please click here.

4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress
2020-03-12 - 2020-03-13 | ILEC Conference Center and IBIS London Earls Court, 47 Lillie Road, London, SW6 1UD
In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London, UK would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.
Key Sessions:

Updates in development of monoclonal antibodies, ADC’s and Bispecific Ab’s
Immune Checkpoint Inhibitors and Combinations
Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immunecheckpoint modulators)
Biomarkers and Cancer Vaccines
CAR-T cell therapy, T Cell Therapy
Tumor microenvironment
Oncolytic Viruses
Microbiome in Cancer Immunotherapy

To learn more about 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress click here

AI in Drug Discovery Conference 2020
2020-03-16 - 2020-03-17 | London, United Kingdom
Leveraging machine learning – discovery to the next level!
SMi group presents the launch of the inaugural AI in Drug Discovery conference taking place in London on 16th-17th March 2020.
AI-empowered machine learning technologies hold the potential of reducing drug discovery associated costs by US$ 70 billion in the upcoming 10 years. With an estimated +39% CAGR, AI in drug discovery is leading the way into a shorter, cheaper and more successful R&D era where compound generation is automated, drug synthesis is predictable and undruggable diseases are finally being targeted.
The presence of AI in drug discovery is tangible with the majority of drug discovery scientist already working with AI-enabled platforms using machine learning and deep learning, neural networks and natural language processing. However, there is a long journey ahead of optimizing AI-human connections and understanding the full potential of AI-enabled tools and platforms.

BENEFITS OF ATTENDING:

Listen to case studies form industry leader pharmaceutical and biotechnology that have already incorporated AI into their work
Explore how Deep Learning Methods can be leveraged for compound screening, de novo design, multiparameter optimization/ ADME toxicity property predictions, chemical synthesis route predictions
Discover strategies for overcoming data-related challenges such as lack of consistent and quality data at the heart of AI and strategies for improving data access
Define unique discovery approaches such as fragment-based drug discovery and network-driven drug discovery

Join us at SMi’s inaugural AI in Drug Discovery 2020 Conference and explore the latest AI-enabled approaches for lead compound screening, multi parameter optimization, disease modelling, drug synthesis and design.
To register please visit: www.AI-indrugdiscovery.com/pharmajwl
PLUS, one interactive half-day post-conference workshop
Practical application of predictive properties in drug design, Workshop Leader: Robert Young, Blue Burgundy Ltd.
Early-Bird Rates

BOOK BY 29TH NOVEMBER AND SAVE £400
BOOK BY 13TH DECEMBER AND SAVE £200
BOOK BY 31ST JANUARY AND SAVE £100

SOCIAL MEDIA HANDLES
Twitter: @SMiPharm #SMiDrugdiscovery
LinkedIn: follow our company page – search ‘SMi Pharma’

Formulation & Delivery Series US
2020-03-17 - 2020-03-18 | Hilton San Diego Mission Valley, 901 Camino del Rio South, San Diego, CA, 92108, United States
Join over 250 leaders, experts and researchers at the Formulation & Drug Delivery US Series, connecting global pharma, biotech and academia for high-level discussions on the latest innovations for biopharmaceutical development.

The Formulation & Drug Delivery Congress will discuss the state of the industry, looking at new strategies for optimizing biologic formulations such as antibodies, proteins and vaccines, as well as highlighting key updates in amorphous solid dispersions and combination products.
Alongside this, The Inhalation & Respiratory Drug Delivery Congress will examine the latest developments in inhaled vaccines and antibiotics, alongside challenges and trends in generic formulation.
Featuring over 55+ renowned industry speakers from leading organisations such as Merck, Takeda and AstraZeneca, this programme will allow you to discuss the key topics that interest you.
View the Programme: https://bit.ly/33nCbI2
2020 Live Webinars:
‘The Design And Development Of A Connected Inhalation System To Help With Monitoring And Patient Adherence’ – Hosted by Paul Upham, Head, Smart Devices, Genentech
“Understanding Supersaturation Of Small Molecule To Improve Oral Bioavailability” – Hosted by Sudhakar Garad, Global Head of Chemical and Pharmaceutical Profiling, Novartis Institutes for BioMedical Research
“Ocular biopharmaceutics: impact of modeling and simulation on topical ophthalmic formulation development” – Hosted by Hovik Gukasyan, Associate Director, Early Development Formulation and Physical Chemistry, Allergan
Webinar Registration: https://bit.ly/2qvy91O
Go Social: For the latest conference updates follow us on Twitter @FDDCongress and join the congress conversation on #FDDUS20
For more information about the event, please contact Guillaume Alonso at g.alonso@oxfordglobal.co.uk

4th Annual Gene Therapy for Rare Disorders
2020-03-30 - 2020-04-02 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market.
With approvals in a number of indications over the last year, and more rapidly approaching on the horizon, the meeting will leverage the experience from first to market pioneers, as well as unveiling the strategies
drug developers are employing to improve efficacy, safety and commercial viability.
Incorporating insights from 80+ industry-leading speakers, this conference will delve into the key regulatory, reimbursement, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies.
Join 600+ of your colleagues to accelerate the progress of the next generation of gene therapies.
This is your comprehensive guide to define your commercial path forward in 2020.
To know more about 4th Annual Gene Therapy for Rare Disorders click here.

Cell Engager Summit
2020-03-30 - 2020-04-01 | Courtyard Boston Downtown, 275 Tremont Street, Boston, MA, 02116, United States
The Cell Engager Summit is the only meeting focused on developing multi-specific cell engaging therapies in liquid and solid tumor indications, accelerating early discovery innovation into the clinic.

Understand the very latest in construct design, immune cell biology, tumor associated activation, toxicity assessment, solid tumor targeting strategies, clinical insights and more.
Discover how to effectively scale complicated manufacturing of multi-specific cell engagers to reduce production costs and time whilst ensuring purity and quality of antibodies.
With 22+ hours of content, 2 interactive workshops and over 5 hours of networking with key industry leaders, this conference will focus solely on cell engaging drugs and how to tackle key clinical and commercial challenges.
To learn more about this event and to register online, visit https://ter.li/hkw9b8

SMi’s 22nd Annual Superbugs & Superdrugs Conference
2020-03-30 - 2020-03-31 | Holiday Inn Kensington Forum, 97 Cromwell Rd Kensington, London, SW7 4DN, United Kingdom
A Focus on Non-traditional Approaches in the Fight against Antimicrobial Resistance
Sponsored by Scynexis
CO-CHAIRS FOR 2020: Cara Cassino, Chief Medical Officer, Contrafect and Michael Dawson, Director, Mike Dawson Antimicrobial Research Consultancy
Announcement: Due to ongoing concerns over COVID-19 this conference is now available with remote access only – please register your place at www.superbugssuperdrugs.com
As one of the most impactful pharmaceuticals for maintaining public health, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal, including colistin, carbapenems, 3rd and 4th generation cephalosporins, useless.

This year’s event aims to showcase a suite of sessions focused on novel drugs and approaches, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR.
It is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020, along with leaders from the pharmaceutical industry, academia, regulatory and funding bodies, and public-private partnerships to discuss the way forward. #SMiBugs
FEATURED SPEAKERS FOR 2020:

Yuri Gleba, Professor, Founder, Nomad Bioscience
Mark Albrecht, Branch Chief, Antibacterials program, BARDA/HHS
Paul Finn, CEO, Oxford Drug Design
Cara Cassino, Chief Medical Officer, Contrafect
Martin Everett, CSO, Antabio
Samareh Lajaunias, Director, Combioxin SA
Francois Moreau, Scientific Director, Mutabilis
Emma Leire, Microbiology Lead, Centauri Therapeutics
Lorenzo Corsini, Co-Founder/CEO/R&D, Phagomed
Stephen Barat, VP, Preclinical Research and Early Development, Scynexis
Colm Leonard, Consultant Clinical Adviser/Consultant Thoracic Physician/Honorary Pro

WHATS ON THE AGENDA FOR 2020?

Discuss the new classes of non-antibiotic antibacterial proteins: Colicins and Colicin-like Bacteriocins from Nomad Bioscience
Gain valuable insight towards fighting severe and resistant infections through neutralising bacterial virulence effectors from Combioxin
Examine a UK project looking at novel value assessment and reimbursement for novel antimicrobials from NICE/Manchester University NHS Foundation Trust
Explore direct lytic agents (DLAs) and their potential as a successful disruptive anti-infective technology with Contrafect
Evaluate the utility of machine learning and AI in antibiotic drug discovery with Oxford Drug Design

To register visit www.superbugssuperdrugs.com/PJWL
EARLY BIRD-RATES

REGISTER BY 29TH NOVEMBER AND SAVE £400http://www.pharmajournalist.com/event/smis-22nd-annual-superbugs-superdrugs-conference/Holiday Inn Kensington ForumHoliday Inn Kensington Forum
REGISTER BY 13TH DECEMBER AND SAVE £200
REGISTER BY 31ST JANUARY AND SAVE £100

3rd Annual Pharma Supply-Chain & Security World 2020
2020-04-01 - 2020-04-02
The Annual Pharma Supply Chain and Security World Summit is back in London for the 3rd time, and this time with more focus on optimizing your supply chain challenges to ensure an agile, responsive, streamlined and secured supply chain. Pharmaceutical companies have to resist the challenges looming from supply chain security lapses to avoid infiltration of counterfeit, diverted, and adulterated drugs entering into the supply chain.
To protect your brand and build a genuine future, Corvus Global Events invites you to Pharma Supply Chain & Security World 2020 – Supply-chain, Drug Serialization And Anti-Counterfeiting conference, which will have Pharma industry experts sharing various challenges faced, new strategies, case studies and use of innovative ideas, the conference will also offer opportunities to encourage partnerships and collaborations. In this conference you’ll not only discover innovative technologies, transformation strategies and collaboration methods, but how best to implement them to optimise your supply chain processes and strategies for drug anti-counterfeiting.
To learn more and to register online, visit: http://bit.ly/2lB3X2E

4th Advanced Sourcing R&D Procurement in Pharma Summit
2020-04-07 - 2020-04-09 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
Join the 4th Advanced Sourcing R&D Procurement in Pharma Summit to: Discover How Can R&D Procurement Enhance SRM, Expedite Speed-to-Market & Deliver Beyond TCO. As the only meeting catered to the needs of senior R&D Procurement, Sourcing and Category Management leaders, we have seen the transformation since we launched this meeting in 2017. Over the last 3 years, we have witnessed the industry begin to mature – procurement leaders play an increasingly important role as strategic business partner and innovation enabler, supporting R&D to progress into clinic and commercialization.
Be part of this growing community where you can share your common challenges and be inspired by fellow colleagues from pharma and biotech. Find out more > https://ter.li/8mwudk

Temperature Controlled Logistics in Biopharmaceuticals US
2020-04-08 | Virtual Event
Temperature Controlled Logistics in Biopharmaceuticals US 2020 is going virtual!
Now in its 4th year, Temperature Controlled Logistics is going VIRTUAL to deliver key, actionable insights into very latest regulatory requirements, technological innovations, strategic developments, and how to implement them into your commercial and clinical logistics with both maximum efficiency and minimal cost.
Temperature Controlled Logistics will bring you everything you need to ensure a successful and compliant implementation for storage and distribution. With a more interactive and hands on agenda including panel discussions; roundtables; speed networking; think tanks; mini workshops and more, this event will create an environment where storage and distribution teams from across all sizes of manufacturer can work together to manage creative, technical, and regulatory demands while ensuring patients are safeguarded at all stages.
Join pharmaceutical, medical device and biotechs experts to discuss new trends and opportunities and learn how to optimize temperature maintenance with the supply chain.

eyeforpharma Philadelphia Virtual
2020-04-14 - 2020-04-17 | Online, PA
“As we self-isolate, we must be careful not to isolate our ideas and thoughts. Ironically, it has never been more important for our industry to share, collaborate and inspire. For that reason, we have not cancelled the eyeforpharma Philadelphia meeting, but we’re moving it online. It is also now entirely free of charge to attend. I’m humbled that the speakers and supporters that were due to present are moving online with us, and share with us a desire to ‘do what we can’ to make sure that we carry on communicating. I believe the event will be stronger than ever, and more influential – at just the right time.”

Paul Simms, Chairman, eyeforpharma
Why eyeforpharma Philadelphia Virtual is essential viewing:

It’s free for all to join: In such a difficult time, we want to unify the industry and we’ve taken the decision to allow anyone to sign up to listen live, ask questions and participate. If you work for a pharma or biotech, you’ll also get access to a full meeting service so you can set up bespoke 1-1 meetings with fellow attendees.

A speaker faculty even better than before: You’ll learn from 100+ speakers with 60+ free sessions – presentations, panels, fireside chats, interactive workshops and Q&A, You’ll also see hours of additional live and on-demand content, including never-before-seen interviews with Kabir Nath, President & CEO North America, Otsuka, Julie Gerberding, EVP and Chief Patient Officer, Communications, Global Policy and Population Health, Merck, James Musick, VP and Head of Digital Transformation, Neurology, UCB, and many more.

Connect with industry leaders around the world: Without the constraints of geography, we’ll have thousands of industry leaders from across the globe coming together to network and collaborate.

Complete virtual meetings platform: Send messages to connect 1-on-1 with your fellow attendees. Schedule meetings and use a virtual private meeting room to chat.

Full virtual exhibition: Showcasing over 50+ exhibitors, search for the latest services and technology solutions from your desk, watch demo videos and the ability to share your virtual business card.

Register for FREE here: https://bit.ly/2UPFCVZ Join the conversation and become healthcare’s solution.

Neuroimmunology Drug Development Summit 2020
2020-04-15 - 2020-04-17 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
More and more pharma and biotech companies are investing in research focused on neuroimmunology and neuroinflammation’s relation to neurodegenerative diseases in the challenge to develop clinically effective therapeutics.

The 2nd Neuroimmunology Drug Development Summit’s agenda has specifically designed alongside neuroimmunology experts from the likes of Denali, AbbVie and Biogen to help these drug developers to overcome their translational challenges and successfully translate their drug candidates into the clinic.
Immerse yourself in the field’s cutting-edge scientific advances and take this unrivaled opportunity to join over 23 expert industry speakers and over 80 drug developers from the neuroimmunological community for over 7 hours of dedicated networking time and 2 deep-dive workshops.
To find out more and view the full speaker line-up, download the full event guide.

2nd Digital Health for Pharma (DH4P)
2020-04-20 - 2020-04-22 | Philadelphia, PA, Philadelphia, PA, United States
Digital Health for Pharma (DH4P) is the leading Digital Health conference specifically developed for pharmaceutical and life science commercial organizations. Co-created by Evolution Road and ExL Events’ Digital Pharma Series teams, the three-day event serves to educate life science organizations on how best to leverage digital tools to enhance the commercial model of health and pharma; while also educating patients and bridging the gap between knowledge and information, pre-commercial and commercialization.

For 2020, ExL Events and strategic partners at Evolution Road explore five core leverage models of learning:

INVEST
INCUBATE/ACCELERATE
COMMERCIALIZE
COLLABORATE
CO-DEVELOP

Learn more: http://bit.ly/2TJ2cOh

9th Digital Marketing for Medical Devices West
2020-04-22 - 2020-04-24 | San Francisco, CA, San Francisco, CA, United States
Digital Marketing for Medical Devices is the premier event in the west coast for medical device companies to explore best practices and innovations to improve their digital marketing strategy. Med device companies will hear from their peers in the industry as well as marketing agencies who will reveal the most effective methods to market their products in a digital age.

The event takes place in San Francisco, one of the largest tech hubs in the world, as the medical device industry in this region is expanding at a rapid pace. DMMD West provides a platform to assist this rapid expansion. From innovation through research and development, marketing and data analytics, communication and branding strategies, and measuring KPIs and ROIs, this event serves to assist your organization, small and large, along your product life cycle.
Learn more: http://bit.ly/39xKlke

Manufacturing Assets & Facility Management in Pharma
2020-04-28 - 2020-04-30 | Wyndham Boston Beacon Hill 5 Blossom Street Boston, MA, MA 02114, United States
Pharma, biotechs and CMOs have witnessed a major transformation with the continued adoption of digital manufacturing and emerging technologies using AI and big data. We have seen pioneers, including the likes of Sanofi and Merck, to maximize asset value, increase plant reliability and ensure production continuity through digitization.
The inaugural Manufacturing Assets & Facility Management (MAFM) in Pharma Summit has been specifically designed to help you manage cost pressures and boost productivity through digitization where you will advance various aspects of asset and facility management programs such as clarity of asset inventory, asset lifecycle, facility footprint and sustainability.

Why is this Event for You? Join this cutting-edge discussion to:

Get up to speed with the digital transformation to streamline operations
Find new approaches to strategic asset management to improve inventory visibility
Use data to enhance asset utilization and track the full lifecycle of assets
Employ energy and sustainability initiatives to reduce utilities spend
Manage MRO processes to improve productivity and reduce costs

Immerse yourself in this industry-led meeting with the likes of Merck, CSL Behring and Seattle Genetics. This event is dedicated to exploring strategies in the manufacturing environment where you will join 60+ senior experts from functions of Manufacturing Engineering, Manufacturing Operations, Facility Management, Asset Management, Procurement and Maintenance & Reliability across pharma, biotech and CMOs.
Register with your team today and don’t miss out on this unique meeting to engage with peers and re-define best practice for tomorrow’s operations.

Recombinant Chromogenic Assay as Alternate Methods for the Bacterial Endotoxins Test (BET)
2020-04-29 | WEBINAR
Recombinant Chromogenic Assay as Alternate Methods for the Bacterial Endotoxins Test (BET)
Conference: 29 April 2020 – 10am EDT (3pm BST – UK time)
Location: WEBINAR
Website: https://www.smi-online.co.uk/pharmaceuticals/webinar/recombinant-chromogenic-assays
HOSTED BY: Associate of Cape Cod
LED BY: Veronika Wills, Manager, Technical Services, Associates of Cape Cod

Recently, there has been a lot of interest associated with the potential use of synthetic (non-animal based) reagents for bacterial endotoxin testing. This webinar will provide an in-depth overview of the global perspective on the use of such reagents, including their regulatory status.
This free to join webinar is sponsored by Associate of Cape Cod, the one hour webinar will focus on executing a recombinant kinetic chromogenic assay, testing samples and detailed data interpretation with the primary focus on comparability of the data with conventional amoebocyte lysate- based assays.
BENEFITS FOR JOINING THE WEBINAR:
This interactive webinar will provide the following benefits:

An overview of global status of recombinant reagents for BET
A session on kinetic chromogenic testing
Data interpretation
Troubleshooting kinetic chromogenic assays
Equivalency of the recombinant reagents to LAL reagents

WHO SHOULD JOIN?

Senior Microbiologists
Lead Scientists
Laboratory Managers
QA Specialists
Drug Substance External Manufacturers
QC Scientists
Heads of Quality
Business Development Managers
Pharmaceutical Microbiology Consultants
Higher Pharmacopoeia Scientists
Analytical Standards Specialists

For full details and to register your free place, please visit: https://www.smi-online.co.uk/pharmaceuticals/webinar/recombinant-chromogenic-assays

NASH Summit Boston
2020-05-04 - 2020-05-07 | 50 Park Plaza at Arlington Street, Boston, MA, 02116-3912, United States
The NASH Summit offers a wide range of cutting-edge debates across 4 conference tracks: discovery, translational, non-invasive biomarker and clinical drug development, in addition to a selection of workshops and seminars. This convivial discussion and networking forum has an extensive program set to help you approach your pipeline for the upcoming year.

Join 80+ speakers, including our conference Chair Jason Campagna, Senior Vice President & Global NASH Lead at Intercept, and 350+ attendees as the community comes together again by addressing their challenges and the consequences of change in the NASH market.

Establish a plan of action to optimize candidate success by evaluating advances and difficulties and learn from the community’s experience
Translate anti-fibrotic efficacy into the clinic by learning about ground-breaking preclinical modalities
Use the latest practical insights into hepatocyte differentiation to improve your target identification by understanding its impact on immune cells, ductular reaction and fibrosis
Examine the payer’s thoughts on the need to biopsy and assess the clinical utility of non-invasive diagnostics in the normal algorithm of care
Connect NASH reduction in phase 2 and NASH resolution in phase 3 while justifying a systemic approach to address NASH in combination, as a manifestation of wider metabolic dysfunction

Download the full event guide or get in touch today for the agenda and speaker line-up!

SMi’s 20th Annual Pain Therapeutics Conference
2020-05-11 - 2020-05-12 | REMOTE ACCESS ONLY
SMi’s 20th Annual Pain Therapeutics Conference
Discover Cutting Edge Research and Novel Therapeutics in the Pipeline
Conference: 11 and 12 May 2020
Location: REMOTE ACCESS ONLY
Website: http://www.pain-therapeutics.co.uk/PharmaJournWL
Announcement: Due to ongoing concerns over COVID-19 this conference is now available with remote access only – please register your place at www.pain-therapeutics.co.uk
The price to be a part of this conference is £999 (remote access) and registration is available via the conference website at www.pain-therapeutics.co.uk
The 20th Annual Conference will overview the current state of pain treatment starting with research essentials including choosing the right preclinical models to overviewing clinical success up to date, highlighting cutting-edge research and evaluating the potential of drug candidates in the pipelines of leading pharmaceuticals.

This year we are introducing the Pain Research Essentials theme to closely observe analgesics drug development from a preclinical point of view. Within this theme talks will address the latest biomarker discoveries, bridging the translational gap, differences of pain pathology across sexes and consequently, the need for distinct gender animal models. This will be topped with a panel discussion around novel drug targets in neuropathic pain treatment.
Presentations on clinical stage research will highlight current struggles of opioid-based treatments and discuss results of treatments with non-opioid targets; such as the recently researched cannabinoid receptor 2, nociception/orphanin FQ peptide (NOP) receptor, ENKephalinase and NGF receptors. Furthermore, neuro-immune interactions and their role in pain pathology will be discussed as an anticipated approach for providing more effective therapy for chronic pain. Additionally, the therapeutic efficacy of neurotoxins will be addressed exploring novel botulinum-based constructs.
Join SMi’s leading Pain Therapeutics Conference which will explore the cutting-edge research of novel therapeutics in the pipeline of leading pharmaceutical companies and discuss solutions for the challenges of understanding pain as a heterogenous disease and the diverse treatment approaches it requires.
Event Hashtag: #SMiPain
View the full agenda: http://www.pain-therapeutics.co.uk/PharmaJournWL
WHO SHOULD ATTEND
Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:

Pain and Migraine
Inflammation
Chronic Pain
Neuropathic Pain
Analgesic pre-clinical development
Anaesthesia and Pain Management
CNS clinical trials
Ion Channel Pharmacology
Pharmacology Intelligence
Translational science
Drug development
Exploratory development

EARLY BIRD-RATES

BOOK BY 28TH FEBRUARY AND SAVE £200
BOOK BY 31ST MARCH AND SAVE £100
